We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Conatus's PSC Candidate Gets Orphan Designation in the U.S.
Read MoreHide Full Article
Conatus Pharmaceuticals Inc.’s shares increased almost 10% after the biotech company announced FDA’s grant of Orphan Drug Designation (ODD) to its pipeline candidate IDN-7314 for treatment of primary sclerosing cholangitis (PSC).
IDN-7314 is an oral pan-caspase protease inhibitor, designed to reduce the activity of enzymes that mediate inflammation and cell death.
Notably, the FDA through its Office of Orphan Products Development, usually grants ODD to only those drugs and biologics which are being developed for a safe and effective treatment, diagnosis or prevention of rare diseases or disorders affecting less than 200,000 people in the U.S. On receiving this status, the company developing it gets entitled to certain benefits and incentives, including a period of marketing exclusivity upon a regulatory approval for the designated indication.
Shares of Conatus have significantly outperformed the Zacks classified Medical Products industry so far this year. The stock rallied 175.4% ahead of the broader industry’s modest gain of 15.6%.
ODD was conferred by the FDA based on positive results from two preclinical studies evaluating IDN-7314 for treatment of PSC. IDN-7314 has demonstrated a reduction in relevant PSC biomarkers in both the studies. This set of data would act as a positive proof of concept for future clinical trials in humans.
Significantly, PSC is a rare chronic liver disease, prone to cause cirrhosis and liver failure. Presently there are no curative or disease-modifying treatments for PSC in the U.S. Hence, approval of the candidate would provide the company with a potential opportunity to address the unmet needs of patients suffering from this disease.
Apart from IDN-7314, another candidate in the company’s portfolio is emricasan, also developed to treat chronic liver disease, including NASH fibrosis. It is presently in phase II development for the given indication. Meanwhile, several phase I and phase II studies are evaluating emricasan across a broad range of liver disease etiologies and stages of progression.
Notably in Dec 2016, Conatus had signed an exclusive option, collaboration and license agreement with Novartis AG (NVS - Free Report) for the worldwide development and commercialization of emricasan.
The company expects to provide an update on IDN-7314 and other candidates in its early-stage pan-caspase inhibitor pipeline, later in 2017.
Regeneron’s earnings per share estimates inched up from $10.16 to $10.52 for 2017 and from $10.90 to $12.10, in the last 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters, with an average beat of 0.45%. Regeneron’s shares have surged 40.6% so far this year.
Bayer’s earnings per share estimates have minutely crawled ahead from $8.28 to $8.85 for 2017 and from $8.80 to $9.52 for 2018, in the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 10.25%. Shares of Bayer have rallied 31.1% so far this year.
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.
Image: Bigstock
Conatus's PSC Candidate Gets Orphan Designation in the U.S.
Conatus Pharmaceuticals Inc.’s shares increased almost 10% after the biotech company announced FDA’s grant of Orphan Drug Designation (ODD) to its pipeline candidate IDN-7314 for treatment of primary sclerosing cholangitis (PSC).
IDN-7314 is an oral pan-caspase protease inhibitor, designed to reduce the activity of enzymes that mediate inflammation and cell death.
Notably, the FDA through its Office of Orphan Products Development, usually grants ODD to only those drugs and biologics which are being developed for a safe and effective treatment, diagnosis or prevention of rare diseases or disorders affecting less than 200,000 people in the U.S. On receiving this status, the company developing it gets entitled to certain benefits and incentives, including a period of marketing exclusivity upon a regulatory approval for the designated indication.
Shares of Conatus have significantly outperformed the Zacks classified Medical Products industry so far this year. The stock rallied 175.4% ahead of the broader industry’s modest gain of 15.6%.
ODD was conferred by the FDA based on positive results from two preclinical studies evaluating IDN-7314 for treatment of PSC. IDN-7314 has demonstrated a reduction in relevant PSC biomarkers in both the studies. This set of data would act as a positive proof of concept for future clinical trials in humans.
Significantly, PSC is a rare chronic liver disease, prone to cause cirrhosis and liver failure. Presently there are no curative or disease-modifying treatments for PSC in the U.S. Hence, approval of the candidate would provide the company with a potential opportunity to address the unmet needs of patients suffering from this disease.
Apart from IDN-7314, another candidate in the company’s portfolio is emricasan, also developed to treat chronic liver disease, including NASH fibrosis. It is presently in phase II development for the given indication. Meanwhile, several phase I and phase II studies are evaluating emricasan across a broad range of liver disease etiologies and stages of progression.
Notably in Dec 2016, Conatus had signed an exclusive option, collaboration and license agreement with Novartis AG (NVS - Free Report) for the worldwide development and commercialization of emricasan.
The company expects to provide an update on IDN-7314 and other candidates in its early-stage pan-caspase inhibitor pipeline, later in 2017.
Conatus Pharmaceuticals Inc. Price
Conatus Pharmaceuticals Inc. Price | Conatus Pharmaceuticals Inc. Quote
Zacks Rank & Key Picks
Conatus currently carries a Zacks Rank #3 (Hold). Better-ranked stocks in healthcare sector are Bayer AG (BAYRY - Free Report) and Regeneron Pharmaceuticals, Inc. (REGN - Free Report) , each sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron’s earnings per share estimates inched up from $10.16 to $10.52 for 2017 and from $10.90 to $12.10, in the last 60 days. The company delivered a positive earnings surprise in two of the trailing four quarters, with an average beat of 0.45%. Regeneron’s shares have surged 40.6% so far this year.
Bayer’s earnings per share estimates have minutely crawled ahead from $8.28 to $8.85 for 2017 and from $8.80 to $9.52 for 2018, in the last 60 days. The company delivered a positive earnings surprise in three of the trailing four quarters, with an average beat of 10.25%. Shares of Bayer have rallied 31.1% so far this year.
Sell These Stocks. Now.
Just released, today's 220 Zacks Rank #5 Strong Sells demand urgent attention. If any are lurking in your portfolio or Watch List, they should be removed immediately. These sinister companies because many appear to be sound investments. However, from 1988 through 2016, stocks from our Strong Sell list have actually performed 6X worse than the S&P 500.
See today's Zacks "Strong Sells" absolutely free >>